Cardiovascular Disease Risk

Atherosclerotic cardiovascular disease (ASCVD) is the slow build-up of cholesterol-bearing plaque in artery walls. Risk is best understood as a combination of particle count (ApoB), cumulative exposure over decades, blood pressure, blood sugar, inflammation and genetic susceptibility — particularly APOE genotype and Lp(a).

Strong evidence · Last reviewed: 2025-06-30

Key facts

Biomarker framework

• ApoB — counts atherogenic particles directly; target < 80 mg/dL general, < 60 mg/dL high-risk
• LDL-C — most studied lipid marker; target depends on overall risk
• Lp(a) — measure once in a lifetime; genetically set; > 50 mg/dL is independent risk
• hsCRP — inflammation marker that adds prognostic information
• Fasting glucose, A1c, blood pressure — independent risk multipliers

Genetic context

• APOE ε4 — higher LDL, higher cardiovascular and Alzheimer's risk
• APOE ε2 — usually lower LDL but can cause type III hyperlipoproteinemia
• LDLR, APOB, PCSK9 — familial hypercholesterolemia (much higher lifetime risk)
• 9p21 region — modest but well-replicated risk locus

What actually moves outcomes

• Lower lifetime ApoB exposure — diet, exercise, weight, and medication when needed
• Blood pressure < 130/80 in most adults
• Don't smoke; limit alcohol
• Cardio 150+ min/week plus resistance training
• Treat sleep apnea, diabetes, kidney disease aggressively

Related in the knowledge graph

Biomarkers

• ApoB — ApoB is the most discriminating single lipid marker for atherosclerotic CV risk. Strong evidence
• LDL-C — Lowering LDL-C reduces major cardiovascular events proportionally to the reduction achieved. Strong evidence

Genes

• APOE — APOE ε4 carriers run higher LDL and ApoB; ε2 carriers can develop type III hyperlipoproteinemia. Strong evidence

FAQ

Should I get an Lp(a) test?

Yes, once in your lifetime. Lp(a) is genetically determined and a strong independent risk factor — knowing your level changes how aggressively to manage the rest of your lipid profile.

Does APOE ε4 mean I'll get heart disease?

No. It increases susceptibility but doesn't determine outcome. ε4 carriers benefit disproportionately from lipid-lowering, low-saturated-fat eating patterns and consistent exercise.

References

1. Sniderman et al., JAMA Cardiology 2019 — PMID 31389978. ApoB is a more discriminating marker of CV risk than LDL-C or non-HDL-C.
2. ESC/EAS Guidelines 2019 — link. ApoB and Lp(a) added to risk assessment alongside LDL-C.

Informational only — not medical advice. Discuss treatment changes with a qualified healthcare professional.